KEAP1 and cancer: This is supported by the common incidence of NRF2 activation through Keap1 or NRF2 mutations in human cancers[24], which further fuels the controversy surrounding whether the anti-cancer effect of SFN can be attributed to its regulation of the NRF2 pathway.